Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC

Clicks: 274
ID: 269841
2018
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
NCT00783718 and NCT00790933; post-results.
Reference Key
i2018guteffect Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Arijs I;De Hertogh G;Lemmens B;Van Lommel L;de Bruyn M;Vanhove W;Cleynen I;Machiels K;Ferrante M;Schuit F;Van Assche G;Rutgeerts P;Vermeire S;;
Journal Gut
Year 2018
DOI
DOI not found
URL
https://www.pubmed.gov/27802155/
Keywords
biopsy National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male aged middle aged Clinical Trial Phase III Randomized Controlled Trial Antibodies Monoclonal Double-Blind Method Multicenter Study Humanized / therapeutic use* Colitis Ulcerative / drug therapy* Gastrointestinal Agents / therapeutic use* gene expression regulation / drug effects principal component analysis intestinal mucosa / pathology ulcerative / metabolism ulcerative / pathology intestinal mucosa / metabolism wound healing / drug effects* colon / pathology intestinal mucosa / drug effects* colonoscopy pmid:27802155 doi:10.1136/gutjnl-2016-312293 ingrid arijs gert de hertogh severine vermeire humanized / pharmacology gastrointestinal agents / pharmacology genome-wide association study / methods infliximab / therapeutic use intestinal mucosa / physiology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.